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Abstract
This study explored the predictors of weight loss following orlistat with a focus on both baseline
variables and changes in beliefs and behaviours occurring over the course of taking the drug. Patients (
?????? ? ) prescribed orlistat completed a questionnaire at baseline and after 6 months concerning their
weight, beliefs and behaviours. By 6 months the majority had lost some weight and showed
improvements in diet. Many had also stopped taking the drug and a large minority reported using it
flexibly as a lifestyle drug. Those who lost most weight showed a decrease in beliefs in a medical
solution, a decrease in unhealthy eating, an increased belief in treatment control and an increased
belief that the unpleasant consequences are both due to their eating behaviour and just part of the
drug. When taken with fatty food orlistat causes symptoms such as anal leakage and oily stools. These
may encourage some patients to focus on the behavioural aspects of their weight problem thus
promoting the dietary changes needed for both short and longer term weight loss. When prescribing
orlistat, clinicians should encourage patients to see the consequences as an education as a means to
promote the effectiveness of this form of medical management.
1. Introduction
Orlistat (Xenical) is currently the only available form of prescribed obesity medication which acts on the
gastrointestinal system and works by reducing fat absorption in the gut which is eliminated in bowel
movements. It also blocks the availability of fat-soluble vitamins (vitamins A, D, E, and K), so patients
may also take a vitamin supplement [1, 2]. Current recommendations suggest that it is used for
patients who have a history of failed weight-loss attempts using behavioural methods and who can
demonstrate at least 2.5 kg weight loss by diet and exercise in the month prior to their first prescription
[1]. It is suggested that patients reduce their daily calorie intake by 500 to 1000 calories to promote
weight loss, and the Dietary Guidelines for Americans recommend that dietary fat is limited to about
30% of daily calories. As a result of its impact upon fat absorption, orlistat has unpleasant side effects
including liquid stools, an urgency to go to the toilet, and anal leakage which are particularly apparent
following a high-fat meal as the drug causes the fat consumed to be removed from the body. Between
1998 and 2005, orlistat prescriptions rose 36-fold from 17,880 to 646,700 and the total cost increased
by over 35-fold. Recent years have seen an additional significant increase in the number and cost of
prescriptions for orlistat [3].
Research has explored the effectiveness of orlistat compared to other drug treatments, placebo, or
behaviour-focused interventions. For example, Padwal et al. [4] reported that patients taking orlistat
lost 2.7 kg more than patients taking placebo, and Avenell et al. [5] carried out a systematic review of
trials involving a combination of diets, drug therapy, exercise, and behaviour therapy and concluded
that adding orlistat to a dietary intervention improved weight loss by 3.26 kg up to 24 months. Research
also indicated that orlistat reduces cholesterol and blood pressure levels and improves glycemic control
when compared to placebo [4]. Similarly, Phelan and Wadden [6] concluded from their review that
adding orlistat to lifestyle modification interventions improves both weight loss and weight-loss
maintenance. Furthermore, in a recent updated meta-analysis, Rucker et al. [7] synthesised the results
of randomised placebo- controlled trials of approved antiobesity drugs in adults aged 18 and over for
Hindawi Publishing Corporation
one to four years. They concluded that with the active drug treatments patients were more likely to
reach 5% and 10% weight-loss thresholds and that weight losses for three key drugs were as follows:
sibutramine: 4.2 kg; rimonabant: 4.7 kg, and orlistat: 2.9 kg. Research therefore indicates that orlistat
can improve weight loss if used alongside behavioural and lifestyle interventions.
There remain, however, two main problems with orlistat as a treatment for obesity. First, although
evidence indicates that it can improve weight-loss outcomes, these improvements are not always
substantial and there is much variability with many patients showing no improvements at all. Second,
research also indicates high attrition rates with patients not adhering to their medication due to the
unpleasant side effects and many stoppings taking the drug entirely or using it selectively according to
the content of their diet. For example, Padwal et al. [4] concluded from their review of randomised
control trials that the mean attrition rate for orlistat was 33% (11 studies, ?????? ? ? ), and Vray et al.
[8] suggested that in clinical practice attrition rates are even higher at 64%–77%. Research has
therefore addressed whether the effectiveness of orlistat can be improved, and some studies have
explored whether specific patients benefit more than others and whether baseline variables predict
outcomes. However, whereas research exploring alternative forms of medical management has
explored a range of clinical, psychological, and behavioural variables as predictors of outcomes (e.g.,
[9–11]),research focusing on orlistat has mainly emphasised laboratory and clinical variables [12]. In
general, however, such studies conclude that the best predictor of outcome following medical
management is initial weight loss, but to date few studies have explored psychological and behavioural
predictors of outcome following orlistat. An alternative approach has addressed the mechanisms of how
orlistat works, and from a medical perspective the main consequence of orlistat is to reduce fat
absorption in the gut. However, due to the unpleasant side effects, Finer has labelled it the “antabuse
effect” [13] as it deters the intake of high-fat foods. Further, Ogden and Sidhu [14] carried out a
qualitative study with patients who had taken orlistat to explore their beliefs about why it either did or
did not facilitate weight loss. The results showed that inline with previous research some patients
stopped taking their medication due to the unpleasant symptoms such as anal leakage or oily stools.
However, the results also showed that these highly visual side effects encouraged some people to
consider their behaviour as a cause of their obesity. Many obese people focus on medical causes of
their problem such as hormones and genetics [15, 16]. The results from this qualitative study of orlistat
users indicated that by, showing patients the fat they have consumed, orlistat can shift patient models
of obesity towards a more behavioural perspective, thus encouraging them to adopt a healthier diet.
Leventhal et al. [17] described the notion of coherence between beliefs about causes and solutions to
any particular medical problem. Inline with this, Ogden and Sidhu [14] argued that orlistat functions by
educating patients and creating coherence between behavioural causes and therefore behavioural
solutions for obesity. To date, however, this process remains untested in a larger quantitative study.
In summary, although orlistat is currently the most commonly prescribed medication for the obese,
there remains much variability in its effectiveness with only a minority of patients showing weight loss.
Research has therefore explored the possible reasons for the effectiveness of orlistat, and whereas
some studies have emphasised baseline characteristics, others have highlighted changes in beliefs and
behaviour brought about by the mechanisms of the drug itself. To date, however, such studies have
focused either on drugs other than orlistat, have been limited in their choice of variables, or have used
small qualitative designs. The present study, therefore, aimed to explore weight loss following a 6-
month course of orlistat and to explore the role of demographics, beliefs, and behaviour in predicting
outcomes in a large sample of patients. Furthermore, inline with a focus on mechanisms, the study
aimed to assess the role of both baseline variables and the changes occurring whilst orlistat was being
taken.
2. Method
2.1. Design
The study used a longitudinal design with measures concerning BMI, experiences of taking orlistat, and
beliefs and behaviour being completed at baseline and six-month followup.
2.2. Sample
Participants who had been prescribed orlistat by the GP and registered on the Xenical support system
(MAP) funded by Roche were invited to take part in the study and sent the baseline questionnaire.
Those who returned the baseline questionnaire were sent a further questionnaire at six months. Only
those who completed the baseline questionnaire within the first three months of starting to take the
medication and returned the 6 month followup questionnaire were included in this study. 566
participants returned both the baseline questionnaire within the first three months of starting to take
orlistat and the 6 month followup questionnaire. This represented a response rate of 36% of total
baseline responders. The University Ethics Committee approved the study. The data presented here
reflect the short-term followup from baseline to six months.
2.3. Procedure
MAP gained initial consent from participants to pass on their contact details to take part in the study. An
information sheet and questionnaire were then sent out to participants by post. Those who returned the
baseline questionnaire were sent a similar followup questionnaire at six months.
2.4. Measures
Baseline and followup questionnaires examined demographics, beliefs about obesity, beliefs about side
effects, and behaviour. All beliefs and behaviour were assessed using items which were rated using a
5-point Likert scale ranging from “not at all” (1) to “totally” (5). For each construct the individual items
5-point Likert scale ranging from “not at all” (1) to “totally” (5). For each construct the individual items
were summated and the reliability of each construct was assessed using Cronbach’s alpha. Most alphas
were above the established cutoff level illustrating acceptable reliability. Some were lower, but this is
generally acceptable if there is diversity in the constructs being measured.
All measures related to the past month were based on previous qualitative research which has explored
people’s beliefs and experiences of taking obesity medication and successful weight loss and
maintenance [14, 18]. Participants also completed the personal and treatment control items of the brief
Illness Perception Questionnaire that assesses participants’ beliefs about their illness [19]. In addition
the healthy and unhealthy eating measures were taken from the World Health Organisation 2001/02
protocol [20], the food frequency questionnaires found in the study by Inchley et al. [21], the seven-
day food diary [22], and consumer market-research report data [23].
2.5. Inclusion/Exclusion Criteria
Participants were included if they registered with the MAP program within a four-month period, were 18
years or over, and had been prescribed orlistat by their GP and if they had completed the baseline
questionnaire within the first three months of starting to take orlistat and also returned the followup
questionnaire at six months.
2.6. Data analysis
The data were analysed to describe the participants’ demographics, differences between responders and
nonresponders, and overall changes in BMI, weight, and behaviour. Further, the data were analysed to
assess the role of baseline demographics, beliefs, and behaviour in predicting improvements in BMI and
to assess the role of changes in beliefs and behaviour over the course of 6 months in predicting
improvement in BMI by 6 months.
3. Results
3.1. Participants’ Demographics and Responders versus Nonresponders
Responders’, to the questionnaire, versus nonresponders’ (at 6 months) demographic variables are
shown in Table 1.
Table 1: Responders versus nonresponders at baseline.
The results showed that the mean age of the people who returned a completed questionnaire at both
time points (responders) was 50 years and that the majority were white, female, not working, married,
educated up until college, and with a mean BMI of 36. Further, the responders and nonresponders
(those who returned the baseline questionnaire but not the followup questionnaire at 6 months) were
comparable on all baseline demographics apart from age with the responders being older than the
nonresponders.
3.2. Overall Changes in BMI, Weight, and Behaviour
Change scores for BMI, beliefs, and behaviour were calculated (T1-T2) and then classified into groups:
weight loss versus no weight loss; decrease in BMI versus no decrease in BMI; improvement in healthy
eating versus no improvement; increased unhealthy eating versus no increase, and for adherence those
who had stopped taking it by 6 months were grouped as “nonadherers”, those who rated their
adherence as “totally” were rated as “adherers”, and those who reported flexible adherence according
(1)
(2)
(3)
(4)
Demographics: participants completed measures of weight, height, BMI, age, sex, and
employment.
Beliefs about obesity: this included measures relating to (i) behavioural causes of obesity (
?????? ? ? ) (e.g., “eating too much,” “not enough exercise”); (ii) medical causes of obesity (
?????? ? ? ) (e.g., “genetics/inheritance,” “slow metabolism”); (iii) behavioural solutions to obesity
(?????? ? ? ) (e.g., “eating fewer calories,” “being more active”); (iv) medical solutions to obesity
(?????? ? ? ) (e.g., “medication,” “surgery”); (v) personal control over weight (e.g., “how much
control do you think you have over your weight”); (vi) treatment control over weight (e.g., “how
much do you think Xenical can help your weight?”).
Beliefs about side effects: participants rated (i) the extent to which they had experienced side
effects (?????? ? ? ) (e.g., “liquid stools,” “bloating”), (ii) the extent to which they believed these
side effects were part of the drug (?????? ? ? ) (e.g., “they are a necessary part of taking the
drug”), and (iii) whether the side effects were caused by eating behaviour (?????? ? ? ) (e.g.,
“they have made me realise what is in different foods”).
Behaviour: participants rated their behaviour in terms of (i) adherence to medication (?????? ? ? )
(e.g., “I take it religiously,” “I stop taking it before a fatty meal” (which was reverse scored)),
(ii) healthy eating (?????? ? ? ) (e.g., healthy snacks (e.g., rice cakes, crackers, and fruit), healthy
cooking (e.g., boil, steam, and cooked meals at home), and healthy food choices (e.g.,
skimmed milk, low-fat cheese, and high intake of fruit and vegetables) (iii) unhealthy eating (
?????? ? ? ) (e.g., unhealthy snacks (e.g., crisps, cakes, and chocolate), unhealthy cooking (e.g.,
shallow fry, deep fry, processed foods), and unhealthy food choices (e.g., full-cream milk, full-
fat butter/margarine, and low intake of fruit and vegetables).
adherence as “totally” were rated as “adherers”, and those who reported flexible adherence according
to what they were eating were recoded as “lifestyle adherers.” These results are shown in Table 2.
Table 2: Descriptive analysis of baseline to 6 months data.
The results showed that by 6 months the majority of the responders had lost weight and decreased
their BMI. The mean weight loss was 4.09 kg (SD: 6.21), the median weight loss was 3.63 kg, and
percentage weight losses were as follows: 0–2 kg: 19.36%; 2.1–5 kg: 28.1%; 5.1–7 kg: 15.9%; 7.1–10 
kg: 17.4%; 10.1 kg: 19.3%. In addition, the majority had increased their healthy eating and decreased
their unhealthy eating and were no longer taking orlistat although a large minority reported either full
adherence or being lifestyle users by 6 months.
3.3. Predictors of Improvement in BMI over 6 Months
The results were then analysed to assess the role of beliefs and behaviour in predicting an
improvement in BMI by 6 months both in terms of baseline and change scores using Multiple Regression
Analysis and using forced entry method.
3.3.1. Baseline Predictors of BMI Improvement
The role of baseline beliefs and behaviour in predicting improvements in BMI are shown in Table 3.
Table 3: Baseline predictors of a decrease in BMI over 6 months.
The results showed that an improvement in BMI was predicted by a greater endorsement of a medical
solution to their weight problem at baseline, accounting for 7.9% of the variance (??????? ? ? , ?????? ? ? ).
No other baseline variables were significant.
3.3.2. Changes in Beliefs and Behaviour as Predictors of BMI Improvement
Change scores in beliefs and behaviour were calculated (T1-T2). The role of these variables in
predicting improvements in BMI is shown in Table 4.
Table 4: Change scores as predictors of improvements in BMI over 6 months.
The results showed that a decrease in BMI over 6 months was predicted by a decrease in endorsing a
medical solution to their weight problem, a decrease in unhealthy eating, an increased belief in
treatment control, and an increased belief that the side effects are both due to their eating behaviour
and just part of the drug, accounting for 17.3% of the variance (??????? ? ? , ?????? ? ? ? ).
4. Discussion
The present study aimed to explore the predictors of weight loss following 6 months after being
prescribed orlistat with a focus on both baseline variables and changes in beliefs and behaviour over
the course of taking the drug.
The results showed that by the end of 6 months three quarters of patients reported both weight loss
and a reduction in their BMI with the majority falling within the expected range inline with previous
outcome studies [4, 5, 7]. The majority also reported an increase in healthy eating and a decrease in
unhealthy eating which provides some support for the impact of orlistat on diet and its use as the
“antabuse effect” [13]. Furthermore, just less than half had stopped taking their medication by 6
months, and a large minority reported using it flexibly in response to their dietary choices which is
consistent with high attrition rates found in previous studies and the use of orlistat as a lifestyle drug
[4, 8].
In terms of predictors of outcomes, only one baseline variable was related to a reduction in BMI by six
months. In particular, the results showed that a greater endorsement of a medical solution to obesity
predicts a greater reduction in BMI by followup indicating that those who have greater expectations of
success for the drug show greater improvements. This finds reflection in the focus on baseline
predictors reported for other forms of medical management (e.g., [9, 10]) but suggests that it would be
difficult to profile those patients at baseline who would most benefit from taking the drug.
The data were also analysed, however, to explore the role of changes in beliefs and behaviour over the
course of taking orlistat and produced more promising results. In particular, those who lost most weight
showed a decrease in beliefs in a medical solution, a decrease in unhealthy eating, an increased belief
in treatment control, and an increased belief that the side effects are both due to their eating behaviour
in treatment control, and an increased belief that the side effects are both due to their eating behaviour
and just part of how the drug works. Therefore, it would seem that taking orlistat may encourage
patients to focus on their behaviour rather than medical factors as solutions to obesity and
subsequently improve their diet and that if such changes in beliefs and behaviour occur, weight loss is
greater. This provides quantitative support for previous smaller-scale qualitative research [14] and
indicates that the highly visual side effects of orlistat, while being unpleasant and a deterrent for some
users, for others may help educate them towards a more behavioural focus on their weight problem.
There are some issues with the study which need to be addressed. First, the study did not include a
control group as the study aimed to explore the predictors of outcomes after taking orlistat rather than
to assess the effectiveness of this drug. The effectiveness of the drug has been explored elsewhere [4].
Second, both diet and weight were assessed using self-report rather than an objective measurement
tool. This means that there may well be inaccuracies in the data as research has shown that people
tend to underestimate both their weight and what they eat. However, for the present study such self-
report measures represented the best means of measuring these variables in a large-scale nationwide
survey as it would not have been feasible to call all participants into the clinic to collect more objective
data. Third, due to the recruitment procedure, participants were generally completing the
questionnaires within the first 3 months of taking orlistat. The baseline data, therefore, reflects their
beliefs and experiences at the start of their course of taking orlistat but does not reflect that, either
before or at the very start of this process. Future research should aim to recruit participants just before
they take their first prescription of orlistat in order to gain a true baseline. Finally, the data does not
show exactly when the participants stopped taking orlistat. However, by followup it is known whether
the participants were currently taking the drug or if they had stopped within the last month. Therefore,
although we do not have an exact marker of when the course of medication was stopped and therefore
when its impact upon beliefs and behaviour ceased to occur, we do have an approximate measure
which enables some assessment of the interrelationships between drug use and beliefs and behaviour
change. Given these limitations, however, the study does provide some insights into the mechanisms of
orlistat with a focus on the role of beliefs and behaviour in predicting weight loss.
5. Conclusions
To conclude, orlistat is currently the only prescribed obesity medication available for obese patients.
Although research indicates that it can promote weight loss, there remains problems with adherence
and much variability in patient outcomes. The present study aimed to explore predictors of outcomes as
a means to improve its effectiveness. The results indicate that changes in beliefs and behaviour
occurring throughout the course of taking orlistat are the best predictors of outcomes rather than
baseline variables. Further, the results indicate that those patients, who show a shift away from a
medical model of their problem towards a focus on their own behaviour and show improvements in
their diet, lose more weight. These results have implications for patient management and the use of
orlistat for weight loss. In particular, orlistat causes unpleasant side effects which may cause
nonadherence. However, rather than conceptualising such side effects as unfortunate, they may be the
very “active” ingredients necessary to bring about change in patients’ behaviour. Therefore, when
prescribing orlistat, clinicians should not only alert patients to the possibility of such consequences of
eating high-fat foods, but also encourage them to focus and learn from them in terms of what they are
eating, what this looks like when it is excluded from their bodies, and what this would do to their
bodies if it had remained inside. Such an emphasis may encourage patients to see these consequences
of the drug if they eat a diet high in fat, as an education, thus enabling them to take more ownership of
their weight problem, in turn facilitating and promoting the changes in eating behaviour necessary for
both short- and longer-term weight loss and maintenance.
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